TAIPEI, Taiwan — WCC Biomedical will present its WINMAP microarray patch (MAP) technology and unveil two new products at the NACDS Total Store Expo (TSE), taking place August 23–25 in San Diego.
Following a strong debut at BIO Asia in Taiwan last month, WCC will demonstrate its microneedle-based patches, which deliver active ingredients through the skin without needles, pain, or traditional injections. The two new products, a homeopathic pain-relief patch and an herbal maca patch, use the company’s dissolvable WINMAP platform and will be showcased alongside partner and investor Synmosa Group.
“Our WINMAP platform sets a new standard for producing microneedles — with an unprecedented combination of high-precision molds, accurate drug loading, and efficient, scalable mass production,” remarked Ta-Jo Liu, Chairman and CEO of WCC Biomedical. “With this first-in-class platform, we aim to demonstrate how MAPs can expand possibilities for nutrition and pharmaceuticals with needle-free, painless delivery.”
WINMAP’s design enables rapid or controlled ingredient release, depending on formulation, and supports scalable manufacturing of over 10 million MAPs annually. The company holds 14 international patents and is raising at least $7 million to expand production, with plans for an IPO in 2027.
Beyond commercial markets, WCC sees potential for WINMAP to improve health equity, especially in low-resource areas where injection-based therapies are difficult to administer.
More information is available at wccbiomedical.com.
